AI assistant
DEXCOM INC — Director's Dealing 2018
Oct 26, 2018
30198_dirs_2018-10-25_1b9b9165-4d6c-47a8-a75d-a527a5750362.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2018-10-23
Reporting Person: DOUBLEDAY RICHARD (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-23 | Common Stock | S | 1636 | $128.6599 | Disposed | 17458 | Indirect |
| 2018-10-23 | Common Stock | S | 100 | $129.78 | Disposed | 17358 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 66804 | Direct |
Footnotes
F1: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $128.34 to $129.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.